{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:09:22Z","timestamp":1789427362060,"version":"build-2803163510"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972800"],"award-info":[{"award-number":["81972800"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203276"],"award-info":[{"award-number":["82203276"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Natural Science Foundation Horizontal Project","award":["H231174"],"award-info":[{"award-number":["H231174"]}]},{"name":"National Natural Science Foundation Horizontal Project","award":["20231030"],"award-info":[{"award-number":["20231030"]}]},{"name":"Suzhou Health Talent Training Project","award":["GSWS2020008"],"award-info":[{"award-number":["GSWS2020008"]}]},{"name":"Suzhou Science and Technology Development Plan","award":["SKY2023044"],"award-info":[{"award-number":["SKY2023044"]}]},{"name":"College Student Innovation and Entrepreneurship Training Program Project","award":["2023xj031"],"award-info":[{"award-number":["2023xj031"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Esophageal squamous cell carcinoma (ESCC) contributes a major therapeutic challenge in gastrointestinal oncology due to its aggressive behavior. Neoadjuvant immunotherapy combined with chemotherapy (NIT) has emerged as a novel treatment strategy for ESCC. However, clinical responses to NIT vary substantially among individuals, and relying solely on PD-L1 expression to predict therapeutic benefit remains insufficient. Therefore, identifying novel biomarkers to evaluate patient responses to NIT is urgently needed. CD39, an ectonucleotidase with ATPase and ADPase activity, plays a critical role in tumor immune evasion. Using integrated immunohistochemical and multiplex immunofluorescence analyses, we systematically evaluated the expression of CD39 and key tumor immune microenvironment markers in ESCC tissues from patients undergoing NIT. Our results showed that the expression levels of CD39, PD-L1, and \u03b1-SMA were significantly higher in the NIT group compared to the surgery-alone group. Moreover, CD39, PD-L1, PD-1, CD8, and \u03b1-SMA were markedly elevated in patients with effective responses to NIT compared to non-responders. Therapeutic response analysis revealed that patients with high co-expression of CD39 and PD-L1 derived greater benefit from NIT. Further subcellular localization analysis indicated that CD39 was expressed in membrane and cytoplasm of tumor cells, stromal cells and T cells. Interestingly, patients exhibiting co-high expression of stromal cell-derived CD39 rather than tumor cell\u2212derived CD39 rather than tumor cell\u2212derived CD39 with PD-L1 demonstrated optimal therapeutic outcomes. These findings suggest that CD39 and PD-L1 play critical roles in modulating the response to NIT and may serve as candidate biomarkers for guiding individualized treatment strategies in ESCC in the future.<\/jats:p>","DOI":"10.1093\/dote\/doag063","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:30:41Z","timestamp":1781004641000},"source":"Crossref","is-referenced-by-count":1,"title":["CD39 and PD-L1 co-expression may serve as potential indicators for evaluating the efficacy of neoadjuvant immunotherapy in esophageal squamous cell carcinoma"],"prefix":"10.1093","volume":"39","author":[{"given":"Hao","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University , No. 899 Pinghai Road, Suzhou, Jiangsu Province 215006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Weifang People\u2019s Hospital , No. 151 Guangwen Road, Weifang, Shandong Province 261071,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University , No. 899 Pinghai Road, Suzhou, Jiangsu Province 215006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University , No. 899 Pinghai Road, Suzhou, Jiangsu Province 215006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilong","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University , No. 899 Pinghai Road, Suzhou, Jiangsu Province 215006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University , No. 899 Pinghai Road, Suzhou, Jiangsu Province 215006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Ju","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University , No. 899 Pinghai Road, Suzhou, Jiangsu Province 215006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tong","sequence":"additional","affiliation":[{"name":"Institute of Thoracic Surgery, The First Affiliated Hospital of Soochow University , No. 899 Pinghai Road, Suzhou, Jiangsu Province 215006,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University , No. 899 Pinghai Road, Suzhou, Jiangsu Province 215006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxiang","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University , No. 899 Pinghai Road, Suzhou, Jiangsu Province 215006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Soochow University , No. 899 Pinghai Road, Suzhou, Jiangsu Province 215006,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingchuan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Soochow University , No. 899 Pinghai Road, Suzhou, Jiangsu Province 215006,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8903-8205","authenticated-orcid":false,"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University , No. 899 Pinghai Road, Suzhou, Jiangsu Province 215006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Clinical Immunology & Jiangsu Key Laboratory of Clinical Immunology, Soochow University , No. 178 Ganjiangdong Road, Suzhou, Jiangsu Province 215021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University , No. 899 Pinghai Road, Suzhou, Jiangsu Province 215006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"3","key":"2026062916300670300_ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2026062916300670300_ref2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1053\/j.gastro.2017.08.023","article-title":"Epidemiology of esophageal squamous cell carcinoma","volume":"154","author":"Abnet","year":"2018","journal-title":"Gastroenterology"},{"issue":"9","key":"2026062916300670300_ref3","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"issue":"34","key":"2026062916300670300_ref4","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.3748\/wjg.v19.i34.5598","article-title":"Epidemiology of esophageal cancer","volume":"19","author":"Zhang","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"2","key":"2026062916300670300_ref5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1056\/NEJMoa1805101","article-title":"Hybrid minimally invasive esophagectomy for esophageal cancer","volume":"380","author":"Mariette","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl 5","key":"2026062916300670300_ref6","doi-asserted-by":"publisher","first-page":"v50","DOI":"10.1093\/annonc\/mdw329","article-title":"Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Lordick","year":"2016","journal-title":"Ann Oncol"},{"issue":"36","key":"2026062916300670300_ref7","doi-asserted-by":"publisher","first-page":"8586","DOI":"10.1039\/D3TB01358H","article-title":"Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies","volume":"11","author":"Guo","year":"2023","journal-title":"J Mater Chem B"},{"issue":"1","key":"2026062916300670300_ref8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12943-019-1074-3","article-title":"The role of exosomal PD-L1 in tumor progression and immunotherapy","volume":"18","author":"Xie","year":"2019","journal-title":"Mol Cancer"},{"issue":"6411","key":"2026062916300670300_ref9","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"issue":"11","key":"2026062916300670300_ref10","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"2026062916300670300_ref11","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study","volume":"21","author":"Huang","year":"2020","journal-title":"Lancet Oncol"},{"issue":"26","key":"2026062916300670300_ref12","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.21.01926","article-title":"Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic Esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study","volume":"40","author":"Shen","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026062916300670300_ref13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol Cancer"},{"key":"2026062916300670300_ref14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.coph.2020.08.003","article-title":"Targeting the A2AR in cancer; early lessons from the clinic","volume":"53","author":"Willingham","year":"2020","journal-title":"Curr Opin Pharmacol"},{"key":"2026062916300670300_ref15","doi-asserted-by":"publisher","first-page":"1011590","DOI":"10.3389\/fimmu.2022.1011590","article-title":"Immune-infiltrating signature-based classification reveals CD103(+)CD39(+) T cells associate with colorectal cancer prognosis and response to immunotherapy","volume":"13","author":"Luo","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"2026062916300670300_ref16","doi-asserted-by":"publisher","first-page":"e1499","DOI":"10.1002\/cti2.1499","article-title":"CD39 expression defines exhausted CD4(+) T cells associated with poor survival and immune evasion in human gastric cancer","volume":"13","author":"Duan","year":"2024","journal-title":"Clin Transl Immunology"},{"key":"2026062916300670300_ref17","doi-asserted-by":"publisher","first-page":"217072","DOI":"10.1016\/j.canlet.2024.217072","article-title":"CD39 transforming cancer therapy by modulating tumor microenvironment","volume":"597","author":"Xu","year":"2024","journal-title":"Cancer Lett"},{"issue":"2","key":"2026062916300670300_ref18","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3892\/ol.2024.14501","article-title":"Synergistic upregulation of PD-L1 in tumor cells and CD39 in tumor-infiltrating CD8(+) T cells leads to poor prognosis in patients with hepatocellular carcinoma","volume":"28","author":"Kang","year":"2024","journal-title":"Oncol Lett"},{"issue":"4","key":"2026062916300670300_ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041184","article-title":"CD39-expressing CD8(+) T cells as a new molecular marker for diagnosis and prognosis of esophageal squamous cell carcinoma","volume":"15","author":"Liu","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2026062916300670300_ref20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.it.2016.04.009","article-title":"Regulation of the T cell response by CD39","volume":"37","author":"Takenaka","year":"2016","journal-title":"Trends Immunol"},{"issue":"2","key":"2026062916300670300_ref21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","article-title":"Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial","volume":"34","author":"Tang","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"2026062916300670300_ref22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1182\/blood-2007-03-081646","article-title":"A2A receptor signaling promotes peripheral tolerance by inducing T-cell energy and the generation of adaptive regulatory T cells","volume":"111","author":"Zarek","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2026062916300670300_ref23","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J Exp Med"},{"issue":"4","key":"2026062916300670300_ref24","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/gutjnl-2021-326553","article-title":"Autologous T cell responses to primary human colorectal cancer spheroids are enhanced by ectonucleotidase inhibition","volume":"72","author":"Bonnereau","year":"2023","journal-title":"Gut"},{"issue":"19","key":"2026062916300670300_ref25","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"7528","key":"2026062916300670300_ref26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"2026062916300670300_ref27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.12688\/f1000research.22926.1","article-title":"Recent advances in treating oesophageal cancer","volume":"9","author":"Harada","year":"2020","journal-title":"F1000Res"},{"issue":"6","key":"2026062916300670300_ref28","doi-asserted-by":"publisher","first-page":"644","DOI":"10.5935\/1678-9741.20150081","article-title":"Alpha-smooth muscle actin and ACTA2 gene expressions in vasculopathies","volume":"30","author":"Yuan","year":"2015","journal-title":"Braz J Cardiovasc Surg"},{"issue":"9","key":"2026062916300670300_ref29","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2026062916300670300_ref30","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.7150\/jca.92230","article-title":"Occurrence and prognosis of mixed subtype adenocarcinoma and adeno-squamous carcinoma in esophageal cancer","volume":"15","author":"Zhang","year":"2024","journal-title":"J Cancer"},{"issue":"7637","key":"2026062916300670300_ref31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"4","key":"2026062916300670300_ref32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"2026062916300670300_ref33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol Rev"},{"issue":"12","key":"2026062916300670300_ref34","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nrc.2017.110","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2026062916300670300_ref35","doi-asserted-by":"publisher","first-page":"837230","DOI":"10.3389\/fimmu.2022.837230","article-title":"Adenosine-A2A receptor pathway in cancer immunotherapy","volume":"13","author":"Sun","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"2026062916300670300_ref36","doi-asserted-by":"publisher","first-page":"855","DOI":"10.6004\/jnccn.2019.0033","article-title":"Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Ajani","year":"2019","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/39\/3\/doag063\/68648388\/doag063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/39\/3\/doag063\/68648388\/doag063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T20:30:14Z","timestamp":1782765014000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doag063\/8721795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doag063","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"value":"1120-8694","type":"print"},{"value":"1442-2050","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,12]]},"article-number":"doag063"}}